• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of cutaneous angiosarcoma with intradermal metastases responding to PD-1 inhibition-based immunotherapy.

作者信息

Danesh Kayla, Hu Jenny C, Kokot Niels, Goldstein Zachary, DeClerck Brittney, Beutler Bryce, Jadvar Hossein, Butcher Katherine, In Gino K

机构信息

Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Department of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, California.

出版信息

JAAD Case Rep. 2025 Jul 9;64:67-70. doi: 10.1016/j.jdcr.2025.05.046. eCollection 2025 Oct.

DOI:10.1016/j.jdcr.2025.05.046
PMID:40933637
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12418878/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/fe91d43fb30c/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/52ac73dff94b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/926a8ff63166/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/32d57f833c50/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/fe91d43fb30c/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/52ac73dff94b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/926a8ff63166/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/32d57f833c50/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abd/12418878/fe91d43fb30c/gr4.jpg

相似文献

1
A case of cutaneous angiosarcoma with intradermal metastases responding to PD-1 inhibition-based immunotherapy.1例伴有真皮内转移的皮肤血管肉瘤对基于PD-1抑制的免疫疗法有反应。
JAAD Case Rep. 2025 Jul 9;64:67-70. doi: 10.1016/j.jdcr.2025.05.046. eCollection 2025 Oct.
2
Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD-L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors.在接受免疫检查点抑制剂治疗的黑色素瘤患者中，使用表达PD-L1的循环小细胞外囊泡监测假性进展
J Extracell Biol. 2025 Jun 22;4(6):e70066. doi: 10.1002/jex2.70066. eCollection 2025 Jun.
3
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.免疫检查点抑制剂联合治疗的益处及肿瘤突变负担在肝细胞癌中的预测作用：系统评价和荟萃分析。
Int Immunopharmacol. 2022 Nov;112:109244. doi: 10.1016/j.intimp.2022.109244. Epub 2022 Sep 18.
4
Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis.在晚期转移性三阴性乳腺癌中确定从PD-1检查点抑制联合化疗中获益最大的亚组：一项系统评价和荟萃分析
World J Surg Oncol. 2024 Dec 21;22(1):346. doi: 10.1186/s12957-024-03424-3.
5
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
6
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
7
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.帕博利珠单抗单药或联合治疗转移性三阴性乳腺癌患者的疗效和安全性：随机对照试验的系统评价和荟萃分析。
Curr Gene Ther. 2024;25(1):72-88. doi: 10.2174/0115665232283880240301035621.
8
A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 & TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review.一名伴有脑转移的IV期肺鳞状细胞癌患者，PD-L1和肿瘤突变负荷高，经免疫化疗和根治性手术后实现完全缓解并长期生存：病例报告及文献综述
Front Immunol. 2025 Jul 4;16:1601125. doi: 10.3389/fimmu.2025.1601125. eCollection 2025.
9
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.非小细胞肺癌患者中 PD-L1 表达和肿瘤突变负担的个体内变异及其对免疫检查点抑制剂治疗结局的影响。
Ann Oncol. 2024 Oct;35(10):902-913. doi: 10.1016/j.annonc.2024.06.014. Epub 2024 Jun 29.
10
Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis.晚期肺癌中根据 PD-L1 表达选择最佳免疫治疗方法：网络荟萃分析。
Future Oncol. 2022 Mar;18(7):883-896. doi: 10.2217/fon-2021-1217. Epub 2021 Nov 26.

本文引用的文献

1
Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab.使用帕博利珠单抗治疗的复发性、肿瘤突变负荷高的头皮皮肤血管肉瘤
Case Rep Oncol. 2023 Nov 28;16(1):1490-1493. doi: 10.1159/000534657. eCollection 2023 Jan-Dec.
2
Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.不同实体瘤接受免疫检查点抑制剂治疗后的假性进展模式。
Cancer Imaging. 2023 Jun 8;23(1):58. doi: 10.1186/s40644-023-00580-9.
3
Dramatic Response of a PD-L1-Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab.
头皮PD-L1阳性晚期血管肉瘤对帕博利珠单抗的显著反应
JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.17.00107.
4
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.程序性死亡配体1（PD-L1）是抗程序性死亡蛋白1（PD-1）治疗的一致性生物标志物吗？Balstilimab在病毒驱动肿瘤中的模型。
Oncogene. 2021 Feb;40(8):1393-1395. doi: 10.1038/s41388-020-01611-6. Epub 2021 Jan 26.
5
Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology.基于正电子发射断层扫描的肿瘤靶向和免疫治疗反应。
Medicina (Kaunas). 2020 Jul 24;56(8):373. doi: 10.3390/medicina56080373.
6
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.免疫治疗后肿瘤假性进展的潜在机制、识别及临床意义
Cancer Biol Med. 2019 Nov;16(4):655-670. doi: 10.20892/j.issn.2095-3941.2019.0144.
7
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.免疫检查点抑制剂治疗的血管肉瘤患者：来自单一机构的七例患者的病例系列。
J Immunother Cancer. 2019 Aug 8;7(1):213. doi: 10.1186/s40425-019-0689-7.
8
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
9
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.抗 PD-1 治疗成功治疗血管肉瘤 - 病例报告。
J Immunother Cancer. 2017 Jul 18;5(1):58. doi: 10.1186/s40425-017-0263-0.
10
Angiosarcoma of the scalp and face: the Mayo Clinic experience.头皮和面部血管肉瘤：梅奥诊所的经验
JAMA Otolaryngol Head Neck Surg. 2015 Apr;141(4):335-40. doi: 10.1001/jamaoto.2014.3584.